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INTRODUCTION
Cutaneous leiomyomas are rare, benign tumors arising from the arrector pili muscle of the hair follicle. They can be found in association with uterine fibroids in multiple cutaneous and uterine leiomyomata syndrome (MCL; OMIM 150800), inherited as an autosomal dominant trait. 1, 2, 3 Association of MCL with familial development of type II renal cell cancer has been characterized in a syndrome called hereditary leiomyomatosis and renal cell cancer (HLRCC; OMIM 605839). 4, 5 Recently, the genetic locus for MCL and HLRCC was mapped to chromosome 1q42.3-43. [3] [4] [5] [6] Subsequently, germline mutations in the fumarate hydratase gene (FH) were found in MCL and HLRCC. [7] [8] [9] [10] Fumarate hydratase is an enzyme that functions as part of the Krebs cycle, responsible for cellular energy production and amino acid metabolism. FH has been predicted to act as a tumor suppressor gene, since loss of the wild-type allele has been found in cutaneous, uterine, and renal tumor biopsies of MCL patients. Moreover, the FH enzymatic activity is low or absent in tumors from individuals with MCL. 7 While the tumorigenic mechanism of FH mutations remains elusive, evidence is clear that dominant mutations in succinate dehydrogenase, also an enzyme of the Krebs cycle, cause tumors of the carotid body and adrenal gland, paraganglioma and pheochromocytoma, respectively. 11 In addition, recessive mutations in the FH gene cause fumarate hydratase deficiency (FHD; OMIM 606812), characterized by neurological impairment, encephalopathy, and premature death in infants. Interestingly, MCL has been reported in the carrier mother of one infant with FHD. 7 However, a recent 4 study has identified other carrier parents of FHD infants who are asymptomatic. Thus, it remains controversial whether all heterozygous FH mutations predispose to MCL. 8 We previously reported five FH mutations in patients affected with MCL, including missense, nonsense, and frameshift mutations. 9 Here, we have identified four novel and three recurrent mutations in seven MCL families, in addition to a recurrent novel splicing mutation, 905-1G>A, in four MCL families. Haplotype analysis of these four families using polymorphic markers surrounding the FH gene provides evidence for a founder effect.
MATERIALS AND METHODS

Human Subjects
We have identified eleven families (MCL- 
Mutation analysis
Genomic DNA was isolated from peripheral blood collected in EDTA-containing tubes using the PureGene DNA Isolation Kit (Gentra Systems, Minneapolis, MN 
RESULTS
Clinical findings
The patients in the eleven families with MCL originated in five different countries, namely, four Jewish families from Israel (MCL-6-9), Ecuador (MCL-10), Spain (MCL-13), Dominican Republic (MCL-15, 16), and the United States (MCL-11,
12 & 14; Fig 1) . These families comprised a total of 11 and 7 affected women and men, respectively, available for this study. Of 96 unaffected members in these families, 13
were available for this study. Skin leiomyomas were found in all of 18 affected individuals and none of the unaffected family members. The patients reported sensitivity of the lesions to cold temperature and touch. The typical skin lesions were firm, skin colored to red, and ranged from a few in number to approximately 100 in older individuals (Fig 2) . The size of the lesions varied between 0.2 to 1.0 cm in diameter and clustered with time.
Of the eleven female patients, nine had coexisting skin and uterine leiomyoma and two of the female patients exhibited skin leiomyoma alone, without any uterine lesion. Five of the patients with affected uteri eventually underwent hysterectomy or myomectomy.
Mutation analysis of the FH gene
We have analyzed eleven families with dominantly inherited MCL for FH mutations. All of the families were found to carry heterozygous mutations in the FH gene (Table 1) . Five of the mutations, H92R, P149L, R190C, 905-1G>A, and 1176del6
represent novel mutations, whereas Q4X, K187R, and R190H, on the other hand, have 8 been previously described. 7, 10 The five novel mutations have not previously been reported in patients with MCL or fumarate hydratase deficiency, nor have they been detected in 142-152 control chromosomes, arguing against them being common polymorphisms.
A G-to-A transition at the invariant G of the 3' acceptor site of intron 6 (905-1G>A) was identified in four families from the Middle East (MCL-6-9) ( Table 1 (mitochondrial amino acid residue 233), and R190H in family MCL-12 (mitochondrial amino acid residue 233). In families with more than one affected individual available for study, MCL-7, 9, 11, 13, cosegregation of the mutation with the disease phenotype was confirmed. Two unaffected carriers, III-3 and III-1, were identified in MCL-6 and MCL15, respectively (Fig 1) .
Haplotype analysis
Closer examination of ancestry revealed that the four Jewish families sharing the 905-1G>A mutation reported ancestors originating from Iran, specifically Tehran (MCL-9 6 and 7) and Shiraz (MCL-8 and 9) (Fig 3) . From these four families, a total of eight affected and nine unaffected family members were available for the study. (Fig 3) , was shown to carry the disease haplotype. Sequence analysis confirmed that he is a carrier of the 905-1G>A splice site mutation.
DISCUSSION
Including our previous work, 6, 9 we have studied a group of 16 MCL families and have identified a total of 13 different mutations accounting for the disease in all families.
Interestingly, previous studies have identified mutations in 60%, 76%, and 89% of the families studied. 7, 8, 10 The observed variability in mutation detection rate may be attributed to the different mutation detection methods employed in each study and to mutations present in the non-coding region. Based on the number of MCL families in which no FH mutations have been detected, it still remains possible that the predisposition to MCL is genetically heterogeneous. Further studies will be necessary to discriminate between undetected mutations and locus heterogeneity.
Pooling the data from this study and our previous report, 6,9 there were 38 affected female patients from 16 MCL pedigrees, including family members not available for mutation studies. Twenty-six affected females developed concurrent skin and uterine lesions (67%), eight of them developed uterine tumors only (20%), and five developed skin leiomyomas only (13%). It remains possible that patients with only uterine leiomyoma may have coexisting skin lesions that are difficult to detect. We have observed in this and our previous study, 6, 9 that patients from the same family may display intra-familial variability of the disease.
Predisposition to type II papillary renal cell carcinoma has been documented in a subset of MCL families. 8 10 The overall frequency of HLRCC is variable depending on the studies, ranging from 1-2% and 14.3%. 8, 10 In addition to type II papillary renal cell carcinoma, association between MCL and collecting duct carcinoma of the kidney has been recently reported. 8, 10, 13 One of the mutations identified in our patient collection is a novel splice site mutation, 905-1G>A, present in four Jewish families recruited in the Middle East (MCL-6-9). The fact that all four families originate from Iran, together with the presence of a common haplotype surrounding the FH gene, suggests that 905-1G>A is most likely a founder mutation. Four previously described FH mutations, N64T, K187R, R190H, and G354R, were also found in multiple families and analysis of three microsatellite markers within the FH gene showed a common haplotype shared by the carriers of each mutation. 8 The missense mutation R190H found in this and two other studies 8,10 deserves special mention. While two of R190H MCL families described by Alam et al 8 originated
from Spain and shared a common haplotype as described above, haplotype analysis of eleven families with the same mutation from North America showed no shared haplotype. 10 In our study, the MCL proband with the R190H mutation is a Caucasian
American. Collectively, the recurrence of R190H mutation in families of diverse ethnic origin and geographic distribution highlights the crucial function of this residue for the activity of the protein. According to the proposed structural model, 8 R190, along with K187 and E312, are required to maintain a charge-charge interaction that is important to stabilize an active site loop. In this regard, it is interesting that two other missense mutations affect this residue, R190L
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The three novel missense changes identified in this study, H92R, R190C, and P149L, have not been identified in a collection of 142-152 control chromosomes.
Although they could still represent rare variants present in the general population, it is noteworthy that 13 out of 21 and 13 out of 20 FH mutations detected thus far were missense mutations. 8, 10 The five missense mutations reported here, H92R, K187R, P149L
R190H, and R190C, affect highly conserved residues among human, pig, rat, mouse, yeast, and E. coli FH (data not shown). As mentioned above, the proposed FH crystal structure suggests that the interaction between K187 and R190 residues, along with E312, would be crucial for the stability of the active site loops. 8 According to the same model, P149 is positioned adjacent to an active site required for tetramerization of the FH protein. Mutations in these highly conserved residues would very likely disrupt the folding and tetramerization of the enzyme.
In addition to nonsense, splice site, and missense mutations, we have also identified a novel 6 bp deletion starting at nucleotide 1176, 1176del6, in MCL-16, resulting in an in-frame deletion of two amino acids, A350 and V351. Amino acid residues A350 and V351 are conserved in human, pig, rat, and mouse FH. The mutation V351L, affecting one of the residues involved in the deletion, was identified in one of our previously reported MCL families. 9 We have identified two unaffected carriers of FH mutations. The first one, III-3 from MCL-6 family (Fig 1) , is a 17-year-old male. Sequence analysis confirmed the haplotype results (Fig 3) , with the identification of the splice site mutation 905-1G>A in III-3 and his mother, II-6, who reported onset of MCL symptoms at the age of 23. Exonskipping is likely to be the mechanism in which the involved exon is spliced out of the 13 mRNA. 14 Skipping of exon 7 would result in an in-frame deletion. Unfortunately, mRNA sample from this family was not available for further testing. The second unaffected carrier identified in our study is a 12-year-old child, III-1 from pedigree MCL-15, who carries the missense mutation H92R (Fig 1) . and uterine leiomyomas, the latter being a major public health issue for women. In addition, the aggressive papillary renal cell carcinoma and collecting duct carcinoma of the kidney can also be associated with MCL, as well as malignant leiomyosarcoma. 5, 8, 10 So far, several groups have studied different types of malignancies, and have found FH mutations in a small number of tumors, including uterine and cutaneous leiomyomas, leiomyosarcomas and soft tissue sarcoma. 12, 15, 16 Two other studies have excluded FH involvement in the pathogenesis of familial and sporadic prostate cancer. 17, 18 Recently, a novel alternatively-spliced transcript of the human alpha-methylacyl-CoA racemase, known to be elevated in prostate cancer, was found to have 88% identity with a 521-bp sequence spanning exons 7-10 of FH. 19 In all, the role of FH mutations in sporadic tumorigenesis remains inconclusive.
The identification of the particular FH mutation in each MCL family will allow for close follow-up of those individuals at risk for the development of the aggressive 14 papillary renal cell cancer and collecting duct cancer of the kidney. 4, 5 The finding of skin leiomyoma in a patient should promote the examination for multiple leiomyomata in this patient as well as in all family members, together with the screening of the FH gene.
Special attention should be paid for the early-onset of uterine fibroids in females and for the existence of kidney cancer in male and females within the family. 
